MENU
+Compare
SBIO
ETF ticker: NYSE ARCA
AS OF
Aug 5, 04:59 PM (EDT)
Price
$33.20
Change
+$0.05 (+0.15%)
Net Assets
76.84M

SBIO stock forecast, quote, news & analysis

The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index... Show more

Category: #Health
SBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for SBIO with price predictions
Aug 04, 2025

SBIO in +1.53% Uptrend, rising for three consecutive days on August 04, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where SBIO advanced for three days, in of 313 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 70 cases where SBIO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on August 04, 2025. You may want to consider a long position or call options on SBIO as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 206 cases where SBIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for SBIO moved out of overbought territory on July 15, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for SBIO turned negative on July 29, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SBIO broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX).

Industry description

The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.

Market Cap

The average market capitalization across the ALPS Medical Breakthroughs ETF ETF is 1.69B. The market cap for tickers in the group ranges from 69.86M to 8.98B. VRNA holds the highest valuation in this group at 8.98B. The lowest valued company is STRO at 69.86M.

High and low price notable news

The average weekly price growth across all stocks in the ALPS Medical Breakthroughs ETF ETF was 71%. For the same ETF, the average monthly price growth was 402%, and the average quarterly price growth was 240%. REPL experienced the highest price growth at 81%, while NMRA experienced the biggest fall at -28%.

Volume

The average weekly volume growth across all stocks in the ALPS Medical Breakthroughs ETF ETF was 3%. For the same stocks of the ETF, the average monthly volume growth was 114% and the average quarterly volume growth was 48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 81
Price Growth Rating: 56
SMR Rating: 100
Profit Risk Rating: 88
Seasonality Score: -11 (-100 ... +100)
View a ticker or compare two or three
SBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
ALPS ETFPO Box 328Denver
Phone
855.724.0450
Web
www.alpsfunds.com